Literature DB >> 9751403

Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.

C X Hsu1, B D Ross, C E Chrisp, S Z Derrow, L G Charles, K J Pienta, N M Greenberg, Z Zeng, M G Sanda.   

Abstract

PURPOSE: Human prostate cancer is variably lethal, shows heterogeneous progression, and exhibits a spectrum of histopathology. Traditional rodent models of prostate cancer lack these characteristics. An alternative, autochthonous model of prostate cancer consists of transgenic mice which develop prostate cancer due to prostatic expression of SV40 T antigen. Lethal progression of such cancers in individual mice has not been previously characterized. Studies were undertaken to characterize the longitudinal progression of prostate cancers in these transgenic mice.
METHODS: A prospective longitudinal cohort study was undertaken to characterize prostate cancer volume, progression, lethality, and histological heterogeneity in a transgenic mouse model of prostatic adenocarcinoma. Fifty-one transgenic mice were followed prospectively to determine the age at onset of palpable tumor and age at cancer-related death. Tumor volume was followed longitudinally by magnetic resonance imaging (MRI) in a subset of these mice and lethal cancers were evaluated by histopathology.
RESULTS: Primary tumors became palpable at 10-38 weeks of age. Palpable tumors always preceded lethal progression. Cancer death followed 2-9 weeks later, and age at cancer death varied from 24 to 39 weeks of age. The histopathological changes were heterogeneous. Primary tumors were detectable by MRI before they became detectable by palpation. MRI showed that, analogous to human prostate cancers, volume of early stage primary tumors did not necessarily predict age at cancer death.
CONCLUSION: Prostate cancer in transgenic mice mimics heterogeneic tumor progression in human prostate cancer, providing a uniquely relevant pre-clinical model. Tumor detection by MRI and palpation are valid surrogate measures of tumor progression in this model.

Entities:  

Mesh:

Year:  1998        PMID: 9751403

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Targeting the prostate for destruction through a vascular address.

Authors:  Wadih Arap; Wolfgang Haedicke; Michele Bernasconi; Renate Kain; Daniel Rajotte; Stanislaw Krajewski; H Michael Ellerby; Dale E Bredesen; Renata Pasqualini; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

2.  The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.

Authors:  Wayne A Fritz; Tien-Min Lin; Richard E Peterson
Journal:  Carcinogenesis       Date:  2008-03-20       Impact factor: 4.944

3.  Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Authors:  Cassie K Chou; Andrea Schietinger; H Denny Liggitt; Xiaoxia Tan; Sarah Funk; Gordon J Freeman; Timothy L Ratliff; Norman M Greenberg; Philip D Greenberg
Journal:  J Immunol       Date:  2012-09-14       Impact factor: 5.422

4.  High spectral and spatial resolution MRI of age-related changes in murine prostate.

Authors:  Sean Foxley; Xiaobing Fan; Sanaz A Jansen; Marta Zamora; Erica Markiewicz; Hikmat Al-Ahmadie; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2008-09       Impact factor: 4.668

5.  The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.

Authors:  Wayne A Fritz; Tien-Min Lin; Stephen Safe; Robert W Moore; Richard E Peterson
Journal:  Biochem Pharmacol       Date:  2008-12-31       Impact factor: 5.858

6.  Optimization of the balanced steady state free precession (bSSFP) pulse sequence for magnetic resonance imaging of the mouse prostate at 3T.

Authors:  Christiane L Mallett; Paula J Foster
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

7.  P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.

Authors:  Tonghui Li; Fangfang Wang; Yanmei Dang; Jiajie Dong; Yu Zhang; Chi Zhang; Ping Liu; Yanhong Gao; Xiaojun Wang; Sijun Yang; Shan Lu
Journal:  Int J Biol Sci       Date:  2019-08-19       Impact factor: 6.580

8.  In vivo MRI volumetric measurement of prostate regression and growth in mice.

Authors:  Kent L Nastiuk; Hui Liu; Mark Hamamura; L Tugan Muftuler; Orhan Nalcioglu; John J Krolewski
Journal:  BMC Urol       Date:  2007-07-24       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.